Business Context and Reporting Period
Company: MESA LABORATORIES INC
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Mesa Laboratories manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, medical sterilization, and pharmaceutical processing. The company operates as a smaller reporting company with no long-term debt.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2009 | Six Months Ended Sept 30, 2009 |
|---|---|---|
| Net Sales | $5,407,000 | $10,383,000 |
| Gross Profit | $3,311,000 | $6,294,000 |
| Gross Margin | 61.2% | 60.6% |
| Net Income | $1,243,000 | $2,269,000 |
| Diluted EPS | $0.38 | $0.69 |
| Operating Cash Flow (6mo) | $3,104,000 | |
| Cash and Equivalents | $11,233,000 (as of Sept 30, 2009) | |
| Current Ratio | 19:1 | |
| Long-Term Debt | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5% in the quarter and 3% for the six-month period compared to the prior year. This was driven by an 18% decline in Datatrace product sales due to delayed capital spending by industrial customers, partially offset by a 9% increase in Raven biological indicator sales.
- Margin Compression: Gross margins decreased to 61% for the quarter (from 64% prior year) and 60.6% for the six months (from 64% prior year). Management attributes this to a product mix shift toward lower-margin Raven products and lower Datatrace sales volumes failing to cover fixed costs.
- Profitability: Net income decreased 8% for the quarter and 4% for the six months. Lower interest income on surplus cash due to softening interest rates also impacted earnings.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased significantly, with selling costs dropping from 13.3% to 11.4% of sales in the quarter due to cost controls and elimination of marginal advertising projects.
- Liquidity Improvement: Cash and cash equivalents increased by $2.1 million during the six-month period, driven by strong operating cash flows of $3.1 million.
Outlook, Risks, and Management Commentary
- Outlook: Management is cautiously optimistic about improving Datatrace sales trends in the second half of fiscal 2010. They anticipate continued cost reduction programs and price increases to improve gross margins.
- Capital Allocation: The company maintains a share repurchase plan (up to 300,000 shares) and a regular quarterly dividend policy ($0.10 per share). No line of credit or debt is currently maintained.
- Risks: Key risks include general economic conditions, changes in capital spending trends, and competition in data logging, kidney dialysis, and biological indicator markets. The filing notes that results of the interim period are not necessarily indicative of full-year results.
- Unusual Items: No unusual items were reported. The company evaluated subsequent events through November 13, 2009, with no material impact noted.
Investor Verification Checklist
- Product Mix Sensitivity: Verify the sustainability of the shift toward Raven products and the potential for further margin compression if Datatrace sales do not recover.
- Capital Spending Trends: Monitor industrial capital spending trends, as Datatrace performance is heavily correlated with customer equipment purchases.
- Interest Rate Exposure: Assess the impact of low interest rates on the company's significant cash surplus ($11.2M), which reduces non-operating income.
- Share Repurchase Activity: Track the execution of the share buyback program (178,906 shares remaining as of Sept 30, 2009) and its impact on EPS.
- Regulatory Costs: Confirm ongoing costs related to Sarbanes-Oxley compliance and any potential increases in regulatory requirements for medical and food processing markets.